Abstract
The perception of HAART failure in achieving broadest immune reconstitution has further strengthened the rationale to widely explore new adjuvant immunotherapy. Most work has been performed on IL-2, given its potential to correct HIV-driven immune defects, possibly translating in enhanced immune competency. This is a literature review report reviewing different trials on IL-2 immunotherapy in HIV/AIDS in the past ten years through the Cochrane and NIH review database. IL-2 can benefit severely compromised patients, either HAART-naive or lacking HAART-driven immune rescue. Furthermore, by sparing HAART-related toxicity, IL-2 is indicated within treatment interruptions or immunization protocols. Important clinical insights stem from the IL-2-mediated immune reconstitution, with a rise in long-term peripheral T-cell turnover, survival and functional markers. Furthermore, IL-2 immunotherapy proved to interfere with cytokine networks with specific regulatory functions over T-cell homeostasis and function. Despite the plethora of immunological findings exploring the intriguing hypothesis that IL-2 might contribute to amend the skewed T-cell immunophenotype and cytokine milieu in HIV/AIDS, major question on the actual clinical impact remain unanswered. This review is meant to thoroughly explore the possibility that the immunological advantages described during IL-2 immunotherapy might translate into actual clinical benefits in the treatment of HIV/AIDS disease.
Keywords: HAART, immune reconstitution, immunotherapy, interleukin-2
Current HIV Research
Title: The Challenge of IL-2 Immunotherapy in HIV Disease: “No through Road” or Turning Point?
Volume: 6 Issue: 3
Author(s): Giulia Marchetti, Camilla Tincati, Antonella d'Arminio Monforte and Andrea Gori
Affiliation:
Keywords: HAART, immune reconstitution, immunotherapy, interleukin-2
Abstract: The perception of HAART failure in achieving broadest immune reconstitution has further strengthened the rationale to widely explore new adjuvant immunotherapy. Most work has been performed on IL-2, given its potential to correct HIV-driven immune defects, possibly translating in enhanced immune competency. This is a literature review report reviewing different trials on IL-2 immunotherapy in HIV/AIDS in the past ten years through the Cochrane and NIH review database. IL-2 can benefit severely compromised patients, either HAART-naive or lacking HAART-driven immune rescue. Furthermore, by sparing HAART-related toxicity, IL-2 is indicated within treatment interruptions or immunization protocols. Important clinical insights stem from the IL-2-mediated immune reconstitution, with a rise in long-term peripheral T-cell turnover, survival and functional markers. Furthermore, IL-2 immunotherapy proved to interfere with cytokine networks with specific regulatory functions over T-cell homeostasis and function. Despite the plethora of immunological findings exploring the intriguing hypothesis that IL-2 might contribute to amend the skewed T-cell immunophenotype and cytokine milieu in HIV/AIDS, major question on the actual clinical impact remain unanswered. This review is meant to thoroughly explore the possibility that the immunological advantages described during IL-2 immunotherapy might translate into actual clinical benefits in the treatment of HIV/AIDS disease.
Export Options
About this article
Cite this article as:
Marchetti Giulia, Tincati Camilla, Monforte d'Arminio Antonella and Gori Andrea, The Challenge of IL-2 Immunotherapy in HIV Disease: “No through Road” or Turning Point?, Current HIV Research 2008; 6 (3) . https://dx.doi.org/10.2174/157016208784325029
DOI https://dx.doi.org/10.2174/157016208784325029 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
HIV vaccine development
The development of a safe and effective vaccine that impedes HIV-1 transmission and/or limits the severity of infection remains a public health priority. The HIV-1/AIDS pandemic continues to have a disproportionate impact on vulnerable and under-served communities in the USA and globally. In the USA, minority communities that have relatively ...read more
Lymphomas in people living with HIV (PLWH)
In the era of combined antiretroviral therapy (cART), the incidence of lymphoma among people living with HIV (PLWH) surpassed Kaposi's sarcoma in 2011, becoming the most common AIDS-defining malignancy. The annual incidence rate ranges approximately from 100 to 300 per 100,000 individuals with HIV infection as the population denominator, which ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Dendritic Cell Immunotherapy for Melanoma
Reviews on Recent Clinical Trials SGK-1 Signalling Pathway is a Key Factor in Cell Survival in Ischemic Injury
Current Drug Targets Oligomerization of G Protein-Coupled Receptors: Computational Methods
Current Medicinal Chemistry Associations of Body Mass Index and Obesity-Related Genetic Variants with Serum Metabolites
Current Metabolomics A Review of Medicinal Plants and Phytochemicals for the Management of Gout
Current Rheumatology Reviews Pharmacotherapy and Prevention of Vascular Dementia
CNS & Neurological Disorders - Drug Targets Emerging Complexity and the Need for Advanced Drug Delivery in Targeting Candida Species
Current Topics in Medicinal Chemistry New Approaches to Chikungunya Virus Vaccine Development
Recent Patents on Inflammation & Allergy Drug Discovery Inflammatory Mediators in Smoke Inhalation Injury
Inflammation & Allergy - Drug Targets (Discontinued) Potential Benefits of Phytochemicals for Abdominal Aortic Aneurysm
Current Medicinal Chemistry Editorial (Thematic Issue: Biologics in Autoimmune Diseases)
Current Pharmaceutical Biotechnology Discovery of Anticoagulant Drugs: A Historical Perspective
Current Drug Discovery Technologies Tissue Plasminogen Activator Prevents Restoration of Tight Junction Proteins Through Upregulation of Angiopoietin-2
Current Neurovascular Research Influence of Polymer Molecular Weight on in-vitro Characteristics and Cytotoxicity of Fulvestrant Loaded Nanoparticles
Current Drug Therapy A Review of Select Recent Patents on Novel Nanocarriers
Recent Patents on Drug Delivery & Formulation Editorial from Editor-in-Chief: Amniotic Pulmonary Embolism and the Respiratory System: Management Trends and Future Options
Current Respiratory Medicine Reviews Targeting Bcl-2 in Herceptin-Resistant Breast Cancer Cell Lines
Current Pharmacogenomics and Personalized Medicine Regulatory Mechanisms of Vanillic Acid in Cardiovascular Diseases: A Review
Current Medicinal Chemistry Therapeutic Potential and Prospects of L-arginine in Various Diseases and its Clinical Intervention
Current Drug Therapy S100A8/A9 as a Pro-inflammatory Cytokine in Obstructive Airway Disease Via the Multi-Ligand Receptor, RAGE
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry